Regenerative medicine for the treatment of heart disease

Journal of Internal Medicine

Volumn 273, Issue 3, 2013, Pages 235-245

  Hansson, E M ^a,b   Lendahl, U ^c  

^a HARVARD UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomaterials; Cell therapy; ES cell; iPS cell; Myocardial infarction; Stem cell

Indexed keywords

ATAXIN 1; BIOMATERIAL; GRANULOCYTE COLONY STIMULATING FACTOR; NEU DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN;

ANGINA PECTORIS; CARDIAC STEM CELL; CARDIOVASCULAR MORTALITY; CELL DIFFERENTIATION; CELL RENEWAL; CELL TRANSDIFFERENTIATION; CELL TYPE; CONGENITAL HEART DISEASE; CORONARY ARTERY BYPASS GRAFT; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; EX VIVO STUDY; HEART ARRHYTHMIA; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HUMAN; MUSCLE CELL; NANOTECHNOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; PARACRINE SIGNALING; PERCUTANEOUS CORONARY INTERVENTION; PLURIPOTENT STEM CELL; PREVALENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; SKELETAL MUSCLE; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL TRANSPLANTATION; HEART FAILURE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; PLURIPOTENT STEM CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING;

EID: 84874000789     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12033     Document Type: Review

References (83)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18.
3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41.
4. Choi WY, Poss KD. Cardiac regeneration. Curr Top Dev Biol 2012; 100: 319-44.
5. Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell 2008; 3: 369-81.
6. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-33.
7. Ghostine S, Carrion C, Souza LC et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106: I131-6.
8. Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-200.
9. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 2002; 34: 241-9.
10. Rubart M, Soonpaa MH, Nakajima H, Field LJ. Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation. J Clin Invest 2004; 114: 775-83.
11. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395-402.
12. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
13. Zimmet H, Porapakkham P, Porapakkham P et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 2012; 14: 91-105.
14. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-209.
15. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-8.
16. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-21.
17. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010; 12: 721-9.
18. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428: 668-73.
19. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-8.
20. Kajstura J, Gurusamy N, Ogorek B et al. Myocyte turnover in the aging human heart. Circ Res 2010; 107: 1374-86.
21. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
22. Kuhn B, del Monte F, Hajjar RJ et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 2007; 13: 962-9.
23. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138: 257-70.
24. Bostrom P, Mann N, Wu J et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010; 143: 1072-83.
25. Hsieh PC, Segers VF, Davis ME et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 2007; 13: 970-4.
26. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-76.
27. Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003; 100: 12313-8.
28. Zhou B, Ma Q, Rajagopal S et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008; 454: 109-13.
29. Bolli R, Chugh AR, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378: 1847-57.
30. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
31. Askari AT, Unzek S, Popovic ZB et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
32. Zhou B, Honor LB, He H et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest 2011; 121: 1894-904.
33. Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25: 1015-24.
34. Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-8.
35. Kinnaird T, Stabile E, Burnett MS et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-9.
36. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006; 98: 1414-21.
37. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50: 280-9.
38. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart from two sources of myocardial cells. Nat Rev Genet 2005; 6: 826-35.
39. Srivastava D. Making or breaking the heart: from lineage determination to morphogenesis. Cell 2006; 126: 1037-48.
40. Laugwitz KL, Moretti A, Lam J et al. Postnatal isl1 + cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005; 433: 647-53.
41. Moretti A, Caron L, Nakano A et al. Multipotent embryonic isl1 + progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006; 127: 1151-65.
42. Stoller JZ, Epstein JA. Cardiac neural crest. Semin Cell Dev Biol 2005; 16: 704-15.
43. Junion G, Spivakov M, Girardot C et al. A transcription factor collective defines cardiac cell fate and reflects lineage history. Cell 2012; 148: 473-86.
44. Bondue A, Blanpain C. Mesp1: a key regulator of cardiovascular lineage commitment. Circ Res 2010; 107: 1414-27.
45. Olson EN. Gene regulatory networks in the evolution and development of the heart. Science 2006; 313: 1922-7.
46. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008; 451: 943-8.
47. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7.
48. Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-14.
49. Passier R, Denning C, Mummery C. Cardiomyocytes from human embryonic stem cells. Handb Exp Pharmacol 2006; 174: 101-22.
50. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132: 661-80.
51. Mummery C, Ward-van Oostwaard D, Doevendans P et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003; 107: 2733-40.
52. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
53. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-5.
54. Polo JM, Liu S, Figueroa ME et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28: 848-55.
55. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-90.
56. Ji J, Ng SH, Sharma V et al. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012; 30: 435-40.
57. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-7.
58. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
59. Xu H, Yi BA, Wu H et al. Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res 2012; 22: 142-54.
60. Moretti A, Bellin M, Welling A et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2011; 363: 1397-409.
61. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-9.
62. Efe JA, Hilcove S, Kim J et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011; 13: 215-22.
63. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51: 987-1000.
64. Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science 2002; 297: 110-3.
65. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455: 627-32.
66. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117: 663-76.
67. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-41.
68. Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011; 9: 504-16.
69. Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142: 375-86.
70. Song K, Nam YJ, Luo X et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012; 485: 599-604.
71. Qian L, Huang Y, Spencer CI et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485: 593-8.
72. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet 2012; 379: 933-42.
73. Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006; 12: 452-8.
74. Sekine H, Shimizu T, Hobo K et al. Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation 2008; 118: S145-52.
75. Shimizu T, Yamato M, Isoi Y et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res 2002; 90: e40.
76. Ott HC, Matthiesen TS, Goh SK et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14: 213-21.
77. Assmus B, Honold J, Schachinger V et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-32.
78. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-94.
79. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-21.
80. Meluzin J, Janousek S, Mayer J et al. Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol 2008; 128: 185-92.
81. van Ramshorst J, Bax JJ, Beeres SL et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009; 301: 1997-2004.
82. Tendera M, Wojakowski W, Ruzyllo W et al. Intracoronary infusion of bone marrow-derived selected CD34 + CXCR4 + cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-21.
83. Hirsch A, Nijveldt R, van der Vleuten PA et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2010; 32: 1736-47.